Treatment outcomes and factors associated with mortality among individuals with both TB and HIV in the antiretroviral era in Thailand

• Main Authors: Sivaporn Gatechompol (Author), Kamon Kawkitinarong (Author), Gompol Suwanpimolkul (Author), Pairaj Kateruttanakul (Author), Weerawat Manosuthi (Author), Jiratchaya Sophonphan (Author), Sa.siwimol Ubolyam (Author), Stephen J. Kerr (Author), Anchalee Avihingsanon (Author), Kiat Ruxrungtham (Author)
• Format: Book
• Published: Elsevier, 2019-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2055-6640; 10.1016/S2055-6640(20)30032-7
• Keywords: treatment outcome; risk factors; TB/HIV; antiretroviral therapy; Microbiology; QR1-502; Public aspects of medicine; RA1-1270
• Source: Journal of Virus Eradication, Vol 5, Iss 4, Pp 225-230 (2019)

Objective: This study aimed to compare treatment outcomes and factors associated with mortality in HIV-1-positive and HIV-1-negative individuals. Methods: We conducted a cohort study between July 2008 and December 2016. Logistic regression was used to determine factors associated with outcomes and death after tuberculosis (TB) treatment. Results: A total of 996 individuals with TB, 228 (22.9%) with HIV-1 co-infection and 770 (77.1%) who were HIV-1 negative were reviewed. The overall treatment success rate was 74.3%. The HIV-1-negative individuals with TB had significantly higher treatment success rates (77.2% vs 64.5%, P>0.001). Using logistic regression analysis, age >50 years (adjusted odds ratio [aOR] 3.89, 95% confidence interval [CI] 2.24-6.76; P>0.001), body weight ≤45kg (aOR 2.19, 95% CI 1.14-4.19; P=0.02) and HIV-1-positive status (aOR 3.31, 95% CI 1.84-5.91; P>0.001) were independently associated with death during TB treatment. Among HIV-1-positive individuals, not undergoing antiretroviral therapy (ART), having diabetes and a CD4 T cell count of >50 cells/mm3 were significantly associated with death. Conclusion: Individuals who had both TB and HIV-1 in Thailand had lower TB treatment success and higher mortality rates compared with individuals with TB without HIV-1. Strategies to improve ART uptake and to reduce risk of developing active TB among individuals with advanced HIV-1 infection should be scaled up.